Bio-Techne Announces Commercial Release Of New Assay For Detecting ASOs, miRNAs, And siRNAs In Tissue

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) has launched the miRNAscope™ Assay, extending its RNAscope™ platform. This novel assay enables the in situ detection of microRNAs and short oligonucleotide therapeutics with single-cell resolution in intact tissues. The miRNAscope Assay addresses significant limitations of traditional methods like PCR and sequencing, offering heightened specificity, sensitivity, and ease of interpretation. Bio-Techne's commitment to enhancing RNA detection demonstrates its leadership in tissue analysis, providing essential tools for researchers in diagnostics and therapy development.

Positive

• Launch of miRNAscope™ Assay enhances product offerings.
• Increased specificity and sensitivity improve research capabilities.
• Addresses critical need for reliable detection of microRNAs in tissues.

Negative

• None.

MINNEAPOLIS, July 20, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope technology is an advanced in situ hybridization assay for the spatial visualization of single-molecule RNA with single-cell resolution directly in intact tissues.

The miRNAscope Assay extends the RNAscope technology to enable the in situ detection of short nucleic acid targets between 17-50 nucleotides which includes an important class of small non-coding RNAs called microRNAs as well as short synthetic oligonucleotide therapeutics such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs). The assay addresses a critical need to reliably detect these ultra-short molecules in native tissue with minimal time and effort, delivering data in an easy to interpret format. Traditional assays such as microarrays, PCRs, and sequencing methods provide useful molecular profiles, but their use with dissociated cells result in the loss of clinically relevant tissue morphological information. The miRNAscope assay utilizes Bio-Techne's patented signal amplification and background suppression technology to deliver researchers with comparatively elevated specificity and sensitivity as well as high signal-to-noise detection. Utilization of this assay enables researchers to perform experiments for various applications such as identifying specific cellular subtypes, visualizing gene regulation, and evaluating therapeutic ASO or siRNA delivery, biodistribution, cellular uptake, and persistence over time, all without compromising the morphological features of the tissue in question.

After obtaining the first data from this technology through the Early Technology Access program, a leading BioPharma Company commented, "We had a great experience using miRNAscope in our compound screening efforts. The technique is incredibly specific, and the results are very easy to understand. Also, working with Bio-Techne's ACD team has been extremely beneficial. They communicated with us during the process to ensure we can get the answers to our questions. They generated impeccable tissue staining!"

Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics Segment, commented, "We are excited to expand our in situ RNA tissue analysis leadership position with the release of the miRNAscope™ Assay. MicroRNAs are an important class of regulatory non-coding RNAs that are gaining more interest from companies in the diagnostic and therapeutic space. In addition, there is an increasing investment level to develop short oligonucleotide-based drugs. Our aim is to provide researchers with a platform to easily and reliably detect these small RNAs and oligonucleotides with single-cell and subcellular resolution in a complex and heterogeneous tissue environment."

The miRNAscope Assay kit from Bio-Techne is intended for research use only. To learn more, visit: https://acdbio.com/mirnascope-assay-red-overview 

About Bio-Techne Corporation (NASDAQ:TECH)

Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-commercial-release-of-new-assay-for-detecting-asos-mirnas-and-sirnas-in-tissue-301095337.html

SOURCE Bio-Techne Corporation

FAQ

What is the miRNAscope™ Assay released by Bio-Techne on July 20, 2020?

The miRNAscope™ Assay is a new tool for detecting microRNAs and short nucleic acids in tissue samples with single-cell resolution.

How does the miRNAscope™ Assay improve RNA detection in tissues?

It offers enhanced specificity and sensitivity compared to traditional methods like PCR and sequencing.

What are the applications of the miRNAscope™ Assay?

Applications include identifying cellular subtypes, visualizing gene regulation, and evaluating drug delivery and uptake.

Why is the miRNAscope™ Assay significant for researchers?

It allows researchers to reliably detect small RNAs in their native tissue environments without losing morphological information.

What company announced the miRNAscope™ Assay?

Bio-Techne Corporation announced the miRNAscope™ Assay on July 20, 2020.